CRNX vs LNTH
Crinetics Pharmaceuticals, Inc. vs Lantheus Holdings — AI-powered side-by-side comparison
CRNX
Crinetics Pharmaceuticals, Inc.
65
Buy
VS
LNTH
Lantheus Holdings
67
Buy
| Metric | CRNX | LNTH |
|---|
| AI Score |
65
|
67
|
| Price |
$84.35
|
$100.63
|
| P/E Ratio |
-16.70×
|
23.91×
|
| ROE |
-46.9%
|
21.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.2%
|
60.1%
|
| Debt / Equity |
0.00×
|
0.44×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
89.2
|
42.5
|
| Beta |
0.1302
|
-0.057
|
| Expected Upside |
—
|
+7.8%
|
AI Committee View
Current Innellis committee reasoning for CRNX versus LNTH.
LNTH leads by 2 points.
LNTH scores 67/100 (Buy) versus CRNX at 65/100 (Buy).
CRNX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 2928.4% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 4.5x prices in significant intangible value — Value
- ROE of only -44.2% -- cheap may mean cheap for a reason — Value
- RSI at 89 is in overbought territory — Technical
LNTH Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical